相关实验视频

Updated: Jan 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

三甲素与患有缺血性心脏病和心房的患者中风风险的改善有关

Yuen-Ting Cheng¹, Gregory Y H Lip^2,3, Bernard M Y Cheung¹

¹Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.

Journal of the American Heart Association

|September 30, 2025

概括

在心房动和缺血性心脏病患者中使用trimetazidine显著降低了新的和复发性中风的风险. 这一发现表明,在这种高风险人群中,对于预防中风有潜在的治疗益处.

科学领域:

心脏病学心脏病学
代谢心脏病学代谢心脏病学
神经学神经学

背景情况:

心肌缺血是心房动 (AF) 患者中风的已知危险因素.
三甲胺优化心肌细胞代谢,优先考虑葡萄糖氧化以缓解心肌缺血.
三甲素对同时患有缺血性心脏病和AF的患者中风风险的临床影响仍在研究中.

研究的目的:

调查三甲素使用与患有缺血性心脏病和AF的患者发生缺血性中风的风险之间的关联.
评估三甲胺对同一患者队列中复发性缺血性中风的作用.

主要方法:

一项回顾性队列研究使用了1999年1月1日至2020年12月31日的数据.
分析了患有缺血性心脏病和AF的患者,不包括先前中风的患者.
考克斯比例回归模型,有或没有倾向分数匹配,将三甲素使用者与非使用者 (长效酸盐) 进行了比较.

主要成果:

这项研究包括12,527名患者 (平均年龄为77.5岁,44.6%是男性).
三甲素的使用独立地与新发性缺血性中风 (HR 0.55;P<0.001) 和复发性缺血性中风 (HR 0.51;P<0.001) 的风险降低有关.
倾向性得分匹配证实了这些发现,显示三甲胺降低了发生性中风的风险 (aHR 0.65;P<0.001).

结论:

在患有同时存在缺血性心脏病和AF的患者中,trimetazidine治疗与新发和复发性中风的发病率较低有关.
这些观察结果突出显示,三甲是这群人中风风险降低的潜在药物.
通过随机对照试验进行进一步验证是有必要的,以确认这些结果.

关键词:

心房动是心房动的一种.缺血缺血症是因为缺血.代谢重编程是指代谢重编程.一次性中风中风中风中风中风三甲胺的使用方法

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

相关概念视频

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...